The American Heart Association and the American College of Cardiology caused a ruckus late last year when they issued new guidelines that, by some measures, would double the number of people who should take a cholesterol-lowering drug, notes Consumer Reports. Lost in the ensuing uproar was a less controversial, but in some ways more far-reaching, recommendation from the same organizations: a renew